CFRX - ContraFect Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
6.96
-0.03 (-0.43%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close6.99
Open7.10
Bid0.00 x 800
Ask0.00 x 1000
Day's Range6.70 - 7.30
52 Week Range2.69 - 13.40
Volume368,134
Avg. Volume353,317
Market Cap193.516M
Beta (5Y Monthly)1.08
PE Ratio (TTM)N/A
EPS (TTM)-3.15
Earnings DateAug 07, 2020 - Aug 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • 2 “Strong Buy” Small-Cap Stocks That Could See Outsized Gains
    TipRanks

    2 “Strong Buy” Small-Cap Stocks That Could See Outsized Gains

    As the number of new COVID-19 infections spikes, so has market volatility. An uptick in cases in the U.S. and China has spurred the latest burst of swings, with both the S&P 500 and Dow Jones following up their three-session winning streaks by heading back to the red on Wednesday.  That being said, one group of stocks has been steadily gaining traction. Small-caps, or names with market caps below $2 billion, have led the pack, with the Russell 2000’s rebound from its March 23 low point exceeding the S&P 500’s gain over the same time period.Taking all of this into consideration, we set out to find compelling small-cap stocks that combine a low cost of entry with the Street’s backing. Using TipRanks’ database, we pinpointed two that fit the bill. Not only are the tickers currently going for less than $8 apiece, but each has also received enough bullish support from analysts to earn a “Strong Buy” consensus rating. The upside potential at play here isn’t too shabby, either.ContraFect (CFRX)Operating within the biotech space, ContraFect is primarily focused on developing biologic therapies for drug-resistant infectious diseases, especially those treated in hospital settings. With multiple key near-term catalysts, some analysts believe that at $6.50 per share, its price tag reflects an attractive entry point.Writing for Cantor, analyst Louise Chen describes her enthusiasm for this name as “infectious." Pointing to the readout of Phase 3 data for exebacase (CF-301), the advancement of CF-370 into and through clinical trials and the identification of an IND candidate for its amurin peptide program, she believes these events could prompt upwards earnings revisions, should the results be favorable.Looking more closely at the first, exebacase is a direct lytic agent (DLA), or group of enzymes targeting the bacterial cell wall leading to immediate bacterial cell death. The candidate showed that it can produce a significant improvement in MRSA patient responder rates, and demonstrated robust levels of safety and tolerability in a Phase 2 study. As a result, Chen thinks the chance of positive results in the Phase 3 DISRUPT study is high.Expounding on this, Chen stated, “We estimate U.S. base case peak sales could be ~$700 million by year five, and in the upside case, peak sales could be ~$1.5 billion. CF-301 has Breakthrough Therapy designation for MRSA bacteremia, Fast Track designation and streamlined development from the FDA.” She added, “Positive Phase 3 data from one study could be enough for U.S. FDA approval.”Speaking to the strength of CFRX’s pipeline, resistant infections increase mortality and costs, and Chen estimates that global mortality was 700,000 in 2016, with this figure expected to reach 10 million in 2050. On top of this, her projections put annual costs in the U.S. at $20 billion and at €1.5 billion in the EU. “New anti-infectives need: 1) superiority data vs. SoC, 2) to show a mortality benefit and 3) to show positive health economics. Currently approved antibiotics do not check these boxes, while CFRX's pipeline will address all these aforementioned factors,” the analyst explained.To this end, the analyst rates ContraFect an Overweight along with a $15 price target. This target implies shares could soar 135% in the next year. (To watch Chen’s track record, click here)  All in all, other analysts are on the same page. 3 Buys and no Holds or Sells add up to a Strong Buy consensus rating. Meanwhile, the $16.33 average price target, which is more aggressive than Chen’s, puts the upside potential at 156%. (See ContraFect stock analysis on TipRanks)Corbus Pharmaceuticals (CRBP)The second stock on our list is Corbus Pharmaceuticals, which develops innovative therapeutics to treat inflammatory and fibrotic diseases. Based on its promising programs, several analysts are getting on board.Representing BTIG, analyst Dae Gon Ha tells investors that this name has been flying relatively under-the-radar. However, given the potential of its lead candidate, lenabasum, this could change.Data from the Phase 3 RESOLVE-1 study evaluating the therapy in systemic sclerosis (SSc) is set to come this summer. Even though the study has been controversial due to the change in endpoint, the analyst argues that “on balance see the change as logical grounded on empirical evidence and physician opinion.” Ha added, “The optics of a changed endpoint notwithstanding, we think the upcoming study is sufficiently powered (>95%) to show clinical efficacy combined with a favorable safety profile.”On top of this, the candidate is also being assessed as a treatment for dermatomyositis (DM). “Behind SSc, DM represents another rare rheumatic disease with a significant market opportunity. Similar to SSc, promising Phase 2 findings were followed with a Phase 3 trial implementing some adjustments (i.e., primary endpoint). Yet despite the differences between SSc and DM, shared features such as multi-organ involvement, skin manifestations, and rampant inflammation suggest that SSc efficacy may provide some readthrough to the probable outcome in DM,” Ha commented.It should also be noted that CRBP has ongoing trials in cystic fibrosis (CF) and systemic lupus erythematosus (SLE), which are being funded externally by the CFF and NIH, respectively. In addition, when comparing the company to Chemocentryx, Ha thinks that if the SSc data de-risks DM, it will imply that CRBP has “an attractive risk/reward profile”.Everything that CRBP has going for it prompted Ha to join the bulls. Initiating coverage with a Buy recommendation, the analyst also set the price target at $22. Should the target be met, a twelve-month gain of 180% could be in store. (To watch Ha’s track record, click here)    Turning now to the rest of the Street, other analysts also take a bullish approach. CRBP’s Strong Buy consensus rating breaks down into only Buys, 4 to be exact. The average price target of $26.50 suggests shares could skyrocket 237% from the current share price of $7.82. (See Corbus stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

  • GlobeNewswire

    Contrafect Announces Publication of Exebacase Phase 2 Study Results in the Journal of Clinical Investigation

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced the publication of the exebacase Phase 2 study results in the July 1, 2020 issue of the Journal of Clinical Investigation. The study results established clinical proof-of-concept for exebacase and informed the design of the ongoing Phase 3 DISRUPT (Direct Lysis of Staph aureus Resistant Pathogen Trial) study of exebacase for the treatment of patients with life-threatening Staph aureus bloodstream infections (BSIs), including right-sided endocarditis.

  • GlobeNewswire

    ContraFect Announces Appointment of Lishan Aklog, M.D. to Board of Directors

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced the appointment of Lishan Aklog, M.D. to the Company’s board of directors (Board). Dr. Aklog is Co-Founder, Chairman and Chief Executive Officer of PAVmed Inc. (PAVM). “Dr. Aklog has a long history of successful leadership and innovation in the healthcare industry, in addition to his expertise in cardiovascular disease and complications,” said Roger J. Pomerantz, M.D., President, Chief Executive Officer, and Chairman of ContraFect.

  • Hedge Funds Never Been Less Bullish On ContraFect Corp (CFRX)
    Insider Monkey

    Hedge Funds Never Been Less Bullish On ContraFect Corp (CFRX)

    In this article you are going to find out whether hedge funds think ContraFect Corp (NASDAQ:CFRX) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks among […]

  • CFRX: Four Abstracts Published in 30th ECCMID Abstract Book; Financing Overhang Removed as Pfizer Makes Second Investment…
    Zacks Small Cap Research

    CFRX: Four Abstracts Published in 30th ECCMID Abstract Book; Financing Overhang Removed as Pfizer Makes Second Investment…

    By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update Four Abstracts Published in 30th ECCMID Abstract Book On May 11, 2020, ContraFect Corp. (NASDAQ:CFRX) announced four abstracts were published in the 30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) abstract book. Both the on-site and online portion of ECCMID 2020 were cancelled due

  • GlobeNewswire

    ContraFect Corporation Announces Private Placement of Common Stock and Warrants to Pfizer Inc.

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of life-threatening infectious diseases, today announced that Pfizer Inc. (PFE) has entered into a stock purchase agreement with ContraFect pursuant to which Pfizer Inc. has agreed to purchase 674,156 shares of ContraFect’s common stock and a warrant to purchase 505,617 shares of ContraFect’s common stock, for approximately $3.0 million in a private placement transaction that is expected to close on May 27, 2020. The private placement is contingent upon the closing of ContraFect’s public offering previously announced on May 21, 2020, and there can be no assurance as to whether or when the private placement may be completed.

  • The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray
    Benzinga

    The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray

    Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 21) * ADC Therapeutics SA (NYSE: ADCT) (IPOed May 15) * Allogene Therapeutics Inc (NASDAQ: ALLO) * AstraZeneca plc (NYSE: AZN) ( announced $1 billion BARDA funding for coronavirus vaccine program) * Biondvax Pharmaceuticals Ltd - ADR (NASDAQ: BVXV) * Cellectis SA (NASDAQ: CLLS) * ChemoCentryx Inc (NASDAQ: CCXI) * Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) * Cue Biopharma Inc (NASDAQ: CUE) * Fate Therapeutics Inc (NASDAQ: FATE) * Harpoon Therapeutics Inc (NASDAQ: HARP) * Horizon Therapeutics PLC (NASDAQ: HZNP) * Intellia Therapeutics Inc (NASDAQ: NTLA) * Kamada Ltd. (NASDAQ: KMDA) * Minerva Neurosciences Inc (NASDAQ: NERV) * Ovid Therapeutics Inc (NASDAQ: OVID) * Passage Bio Inc (NASDAQ: PASG)(FDA granted Rare Pediatric Disease designation to its gene therapy PBGM01 broadly for the treatment of GM1 gangliosidosis) * Soleno Therapeutics Inc (NASDAQ: SLNO) * Surface Oncology Inc (NASDAQ: SURF)Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 21) * Akorn, Inc. (NASDAQ: AKRX) (filed for Chapter 11 bankruptcy) * Digirad Corporation (NASDAQ: DRAD) * Genfit SA (NASDAQ: GNFT)Related Link: These 6 Coronavirus Vaccine Candidates Are The Likeliest To Succeed, Says Morgan StanleyStocks In Focus Aquestive's Partnered Parkinson's Drug Gets FDA Nod Aquestive Therapeutics Inc's (NASDAQ: AQST) development partner Sunovion announced FDA approval for Kynmobi sublingual film - APL-130277 - for the acute, intermittent treatment of OFF episodes in patients with Parkinson's disease. The drug is expected to be available in the U.S. pharmacies in September.Following the approval, Aquestive said it plans to monetize its PharmFilm based therapies."We continue to expect that we will receive between $50 to $100 million of non-dilutive capital from the monetization, in one or a series of transactions," the company said.The stock rose 5.2% to $6.47 in after-hours trading.Syndax's Lead Breast Cancer Drug Flunks Late-stage Study Syndax Pharmaceuticals Inc (NASDAQ: SNDX) said a late-stage study that evaluated its investigational compound entinostat along with exemestane in patients with HR+, HER2- breast cancer who have progressed on a non-steroidal aromatase inhibitor did not achieve the primary endpoint of demonstrating a statistically significant overall survival benefit over hormone therapy alone.The study was conducted by ECOG-ACRIN Cancer Research Group and sponsored by the National Cancer Institute.The stock slumped 19.41% to $16.52 in after-hours trading.Tiziana To Spin-off Its Personalized Medicines Businesses TIZIANA LF SCIE/S ADR (NASDAQ: TLSA) said it intends to demerge its StemPrintER and SPARE genomics-based personalized medicine businesses into a separate company and effect a capital reduction to facilitate the spin-out and listing of StemPrintER as an independent entity.Amarin To Support Pilot Study Of Vascepa In Treating COVID-19 Amarin Corporation plc (NASDAQ: AMRN) said it supports a clinical trial to investigate the effects of its Vascepa on inflammatory biomarkers and other patient outcomes in individuals with COVID-19. The trial is sponsored by the Canadian Medical and Surgical Knowledge Translation Research Group, the company said.Separately, generic pharma company Hikma Pharmaceuticals announced its wholly-owned U.S. subsidiary Hikma Pharmaceuticals USA Inc. has received FDA approval for its generic equivalent to Vascepa.In pre-market trading Friday, Amarin stock was adding 3.85% to $7.56.Navidea Reports Positive Mid-stage Results For Rheumatoid Arthritis Treatment Navidea Biopharmaceuticals Inc (NYSE: NAVB) announced positive preliminary results from the second interim analysis of its ongoing NAV3-31 Phase 2B study"Analysis demonstrates that these interim data further corroborate Navidea's hypotheses that Tc99m tilmanocept imaging can provide robust, quantitative imaging in healthy controls and in patients with active rheumatoid arthritis, and that this imaging can provide an early indicator of treatment efficacy in patients with active RA," the company said.The stock was seen skyrocketing 65.35% to $2.10 in pre-market trading.Roche Buys Gene Sequencing Tech Company Roche Holdings AG (OTC: RHHBY) announced acquisition of Stratos Genomics, an early-stage sequencing technology company to advance the development of its nanopore sequencer.The company did not disclose the financial terms of the dealTetraphase Deems Melinta's Latest All-Cash Offer As Superior, Notifies AcelRx Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH), which has been pursued by multiple companies, said its board has determined that the latest proposal from Melinta Therapeutics, Inc. is a "Superior Offer."'Melinta has offered $27 million in cash, plus an additional $12.5 million in cash potentially payable under contingent value rights to be issued in the proposed acquisition.View more earnings on IBBTetraphase, which agreed to a deal to be bought byAcelRx Pharmaceuticals Inc (NASDAQ: ACRX), said it has informed about its determination concerning the Melinta offer and given AcelRx time until May 29 to either terminate the merger or revise the terms of the merger.Incidentally, La Jolla Pharmaceutical Company (NASDAQ: LJPC) had also tabled an offer for Tetraphase.In pre-market trading, AcelRx shares were adding 2.74% to $1.50.Amag Divests Intrarosa For Upto $125M AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) said it has completed the sale of its rights to Intrarosa to Millicent Pharma Limited, for up to $125 million, including upfront fixed consideration of $20 million and contingent, sales-based milestone payments of up to $105 million.The company said the sale is consistent with its previously announced strategic decision to divest its women's health assets. It also said it remains committed to the divestiture of Vyleesi and associated expense reductions as previously announced.Offerings ContraFect Corp Stock (NASDAQ: CFRX) said it has priced its underwritten public offering of 11.8 million shares of its common stock and related warrants to purchase 8.85 million shares. The gross proceeds from the public offering will be approximately $52.5 million, it said. All shares in the public offering are to be sold by ContraFect.In premarket trading Friday, the stock was slipping 11.87% to $4.75.Hoth Therapeutics Inc (NASDAQ: HOTH) priced its underwritten public offering of 1.82 million shares of common stock at $2.75 per share, for raising gross proceeds of $5 million. The offering is expected to close on or about May 27.The stock was slipping 5.36% to $3 in premarket trading Friday.Dynavax Technologies Corporation (NASDAQ: DVAX) priced its previously announced underwritten public offering of 14 million shares of its common stock at $5 per share. The gross proceeds to Dynavax from the offering are expected to be approximately $70. The offering is expected to close on or about May 27.The stock was retreating 10.25% to $5.08 in premarket trading Friday.PPD Inc (NASDAQ: PPD) said it upsized and finalized the terms of the offering of $500 million aggregate principal amount of 4.625% senior notes due 2025 and $700 million aggregate principal amount 5.000% senior notes due 2028. The aggregate principal amount of the notes to be issued in the offering was increased to $1.2 billion from the previously announced $700 million, the company said.In premarket trading Friday, the stock was adding 1.23% to $28.Geron Corporation (NASDAQ: GERN) said it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of its common stock in an underwritten public offering. All the securities earmarked for the offering are being sold by the company.The stock was slipping 20.92% to $1.55 in pre-market trading.On The Radar Clinical Readouts Atara Biotherapeutics Inc's (NASDAQ: ATRA) abstract on the Phase 1 data for ATA188 in multiple sclerosis, regarding its European Academy for Neurology presentation, will be made available online at 12:30 pm ET.Earnings Teligent Inc (NEW JERSEY) (NASDAQ: TLGT)IPO Inari Medical, a medical device company, priced its upsized initial public offering of 8.203 million shares of its common stock at $19.00 per share, for total gross proceeds of approximately $156 million. The company had earlier planned for a 7.33-million stock offering, with an estimated price of $17-$18 per share. The shares are to be listed on the Nasdaq under the ticker symbol NARI.See more from Benzinga * The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive * The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic Test * The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces .34B Common Stock Offering(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • GlobeNewswire

    ContraFect Corporation Prices Approximately $52.5 Million Public Offering of Common Stock and Warrants

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of life-threatening infectious diseases, today announced the pricing of its underwritten public offering of 11,797,752 shares of its common stock and related warrants to purchase 8,848,314 shares of common stock with an exercise price of $4.90 per share, in exchange for consideration equating to $4.45 for one share of common stock and a warrant to purchase 0.75 shares of common stock. The gross proceeds from the public offering will be approximately $52.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ContraFect. All shares in the public offering are to be sold by ContraFect.

  • GlobeNewswire

    ContraFect Corporation Announces Proposed Public Offering of Common Stock and Warrants

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of life-threatening infectious diseases, today announced that it has commenced an underwritten public offering of shares of its common stock and warrants to purchase additional shares of its common stock. The public offering is subject to market conditions, and there can be no assurance as to whether or when the public offering may be completed, or the actual size or terms of the public offering. All of the securities in the public offering are to be sold by ContraFect.

  • GlobeNewswire

    ContraFect Reports First Quarter 2020 Financial Results and Provides Business Update

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced financial results for the first quarter ended March 31, 2020. “We began 2020 in stride, enrolling patients into our Phase 3 DISRUPT superiority study of exebacase and then receiving Breakthrough Therapy designation from the FDA for exebacase for the treatment of MRSA bloodstream infections,” said Roger J. Pomerantz, M.D., President, Chief Executive Officer, and Chairman of ContraFect. In February, the Company announced that that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to exebacase for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (bacteremia), including right-sided endocarditis, when used in addition to standard-of-care (SOC) anti-staphylococcal antibiotics in adult patients.

  • GlobeNewswire

    ContraFect Announces Four Abstracts Published in the 30th ECCMID Abstract Book

    YONKERS, N.Y., May 11, 2020 -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents.

  • GlobeNewswire

    ContraFect Announces Dr. Roger J. Pomerantz, Chief Executive Officer and Chairman, Invited as Keynote Speaker and Presenter in Maxim’s Infectious Disease Virtual Conference

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that Roger J. Pomerantz, M.D., F.A.C.P., President, Chief Executive Officer, and Chairman of ContraFect, will deliver the keynote address to open Maxim’s Infectious Disease Virtual Conference to be held on May 5, 2020. Dr. Pomerantz will discuss the urgent need for new antimicrobials and the medical attributes required to provide the basis for a renaissance in the anti-infectives sector.

  • GlobeNewswire

    ContraFect to Chair and Participate in Virtual Superbugs & Superdrugs 2020 Conference

    YONKERS, N.Y., March 30, 2020 -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents.

  • We're Keeping An Eye On ContraFect's (NASDAQ:CFRX) Cash Burn Rate
    Simply Wall St.

    We're Keeping An Eye On ContraFect's (NASDAQ:CFRX) Cash Burn Rate

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • GlobeNewswire

    ContraFect Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

    YONKERS, N.Y., March 18, 2020 -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents.

  • GlobeNewswire

    ContraFect to Present at FDA Workshop on Advancing Animal Models for Antibacterial Drug Development

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that Cara Cassino, M.D., the Company's Executive Vice President of Research and Development and Chief Medical Officer, will serve as a panel member at the invitation of the Food and Drug Administration (FDA) and provide industry perspective at the FDA’s public workshop entitled “Advancing Animal Models for Antibacterial Drug Development”. The public workshop will be held on March 5th 2020 at the FDA’s White Oak campus in Silver Spring, MD.

  • GlobeNewswire

    ContraFect Announces U.S. FDA Grants Breakthrough Therapy Designation to Exebacase for the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia, Including Right-Sided Endocarditis

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to exebacase for the treatment of MRSA bloodstream infections (bacteremia), including right-sided endocarditis, when used in addition to standard-of-care (SOC) anti-staphylococcal antibiotics in adult patients.

  • GlobeNewswire

    ContraFect Announces One-for-Ten Reverse Stock Split

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced a one-for-ten reverse stock split of its shares of common stock. Stockholders of ContraFect approved an amendment to the Company’s Certificate of Incorporation to effect the reverse stock split at a Special Meeting of Stockholders held on January 31, 2020. The reverse stock split is intended to give ContraFect greater flexibility in considering and planning for future potential business needs and to increase the per share trading price of the Company’s common stock to satisfy the $1.00 minimum price requirement for continued listing on The Nasdaq Capital Market.

  • GlobeNewswire

    ContraFect Appoints Jane E. Ambler, Ph.D. as Vice President of Clinical Microbiology

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that Jane E. Ambler, Ph.D. has been appointed as Vice President of Clinical Microbiology. Dr. Ambler will lead the the Company’s microbiology efforts in support of the pivotal Phase 3 DISRUPT (Direct Lysis of Staph aureus Resistant Pathogen Trial) superiority study of exebacase in patients with Staphylococcus aureus bacteremia, including right-sided endocarditis and in advancement of the Company’s pipeline of DLAs. Dr. Ambler has over 25 years of experience in clinical laboratory microbiology and antimicrobial drug development, and she has numerous book and journal publications.

  • GlobeNewswire

    ContraFect Announces Oral Presentations at the 30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including Lysins and Amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that it has been granted two oral presentations at the 30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) to be held from April 18-21, 2020, in Paris, France. The oral presentations include new data demonstrating the ability of the Company’s lead compound, exebacase, to resensitize methicillin-resistant Staph aureus (MRSA) to methicillin-derivatives in an animal model of infective endocarditis. Exebacase is currently being studied in the Pivotal Phase 3 DISRUPT (Direct Lysis of Staph aureus Resistant Pathogen Trial) study of exebacase in patients with Staph aureus bacteremia, including right-sided endocarditis.

  • GlobeNewswire

    ContraFect to Present at 2020 ASM Biothreats

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that Cara Cassino, MD, Chief Medical Officer and Executive Vice President of Research has been invited to discuss the potential role of DLAs to combat high consequence biodefense and biologic threats at 2020 American Society of Microbiology (ASM) Biothreats, being held January 28 – 30, 2020 at the Hyatt Regency Crystal City in Arlington, Virginia. Dr. Cassino will also discuss the potential role of the Company’s lead product candidate exebacase, currently being studied in a pivotal Phase 3 trial, in addressing the downstream threat of hospital-acquired MRSA bacteremia for a potential bio-threat exposure with mass casualty events.

  • CFRX: Phase 3 DISRUPT Trial Underway…
    Zacks Small Cap Research

    CFRX: Phase 3 DISRUPT Trial Underway…

    By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update Phase 3 DISRUPT Trial Underway On January 10, 2020, ContraFect Corp. (NASDAQ:CFRX) announced the first patient has been dosed in the Phase 3 DISRUPT (Direct Lysis of Staph aureus Resistant Pathogen Trial) study of exebacase in patients with Staphylococcus aureus bacteremia, including right-sided endocarditis

  • GlobeNewswire

    ContraFect Partners with Leading Orthopedic Center in Europe to Provide Compassionate Use of Exebacase to Patients with Chronic Staphylococcal Prosthetic Joint Infections

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that it has extended early access to exebacase to individual named patients with chronic post-operative prosthetic joint infections (PJIs) under Temporary Authorizations for Use (ATUs) from the French National Agency for Medicines and Health Products Safety (ANSM) in collaboration with Dr. Tristan Ferry at the Hôpital de la Croix Rousse in Lyon, France. Based on promising clinical signals in these exebacase-treated patients, temporary authorization for use of exebacase has now been extended to patients with Staphylococcal PJI occurring early in the postoperative period, to potentially avoid significant loss of function.

  • GlobeNewswire

    ContraFect Announces First Patient Dosed in Pivotal Phase 3 DISRUPT Study of Exebacase as a Treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced the first patient has been dosed in the Phase 3 DISRUPT (Direct Lysis of Staph aureus Resistant Pathogen Trial) study of exebacase in patients with Staph aureus bacteremia, including right-sided endocarditis.